Effect of bcl-2 antisense oligodeoxynucleotides on drug sensitivity of leukemic cells

Hematology Journal

Volumn 4, Issue 3, 2003, Pages 187-197

  Zhang, Yuan ^a   Lei, Xiao Yong ^a  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

Antisense oligodeoxynucleotide (AS ODN); bcl 2; Computational prediction; Drug sensitivity; Leukemia

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; IC 50; IMMUNOCHEMISTRY; LEUKEMIA CELL; RNA STRUCTURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; LEUKEMIA; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0038729632     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200245     Document Type: Article

References (17)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
2. Banerjee D, Bertino JR. Myeloprotection with drug-resistance genes. Lancet Oncol 2002; 3: 154-158.
3. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol/Oncol Clin North Am 1995; 9: 451-465.
4. Crooke ST, Graham MJ, Zuckerman JE, Brooks D, Conklin BS, Cummins LL et al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther 1966; 277: 923-937, 1996.
5. Graham MJ, Crooke ST, Monteith DK, Cooper SR, Lemonidis KM, Stecker KK et al. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther 1988; 286: 447-458.
6. Pepper C, Hooper K, Thomas A, Hoy T, Bentley P. Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells. Leukemia Lymphoma 2001; 42: 491-498.
7. Tolcher AW. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin Oncol 2001; 28(4 Suppl 15): 67-70.
8. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 2000; 6: 2492-2500.
9. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 1812-1823.
10. Klasa RJ, List AF, Cheson BD. Rational approaches to design of therapeutics targeting molecular markers. Hematology (Am Soc Hematol Educ Program) 2001; 1: 443-462.
11. Zuker M. On finding all suboptimal foldings of an RNA molecule. Science 1989; 244: 48-52.
12. Walton SP, Stephanopoulos GN, Yarmush ML, Roth CM. Prediction of antisense oligonucleotide binding affinity to a structured RNA target. Biotechnol Bioeng 1999; 65: 1-9.
13. Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 2000; 92: 34-41.
14. Sohail M, Southern EM. Selecting optimal antisense reagents. Adv Drug Deliv Rev 2000; 44: 23-34.
15. Song HF, Tang ZM, Yuan SJ, Zhu BZ. Application of secondary structure prediction in antisense drug design targeting protein kinase C-alpha mRNA and QSAR analysis. Acta Pharmacol Sin 2000; 21: 80-86.
16. Mathews DH, Sabina J, Zuker M, Turner DH. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure? J Mol Biol 1999; 288: 911-940.
17. Mathews DH, Burkard ME, Freier SM, Wyatt JR, Turner DH. Predicting oligonucleotide affinity to nucleic acid targets? RNA 1999; 5: 1458-1469.